en · de · es · pt
thymosin-alpha-1-notes.peptides7501.com › Info › Research History And Clinical Assessment — Deep Dive

Research History And Clinical Assessment — Deep Dive

By Editorial Desk · published 2025-10-28 · last reviewed 2025-12-08 · Info

免疫组织 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-08. Anything still debated is marked as such rather than presented as settled.

Research History and Clinical Assessment

Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.

Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.

Molecular Identity Of Thymosin Alpha-1

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Thymosin-alpha-1 at a glance

PropertyValueNotes
First described1977Reported as a component of thymosin fraction 5
Sequence length28 amino acidsN-terminal residue is acetylated
Net charge at neutral pHNegativeReflects a high proportion of acidic residues
Principal studied usesChronic hepatitis B and vaccine adjuvantResearch uses outnumber approved indications
Regulatory statusApproved in a limited number of countriesNot approved in the United States or most of Europe

Molecular Background and Identity

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Related pages on this site

Handling, Storage, and Analytical Verification

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

Molecular Structure and Biological Background

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

分子身份与天然来源

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Notes from published material

== History == Vitamin A toxicity is known to be an ancient phenomenon; fossilized skeletal remains of early humans suggest bone abnormalities may have been caused by hypervitaminosis A, as observed in a fossilised leg bone of an individual of Homo erectus, which bears abnormalities similar to those observed in people suffering from an overdose of Vitamin A in the present day. Vitamin A toxicity has long been known to the Inuit, as they will not eat the liver of polar bears or bearded seals due to them containing dangerous amounts of Vitamin A. It has been known to Europeans since at least 1597 when Gerrit de Veer wrote in his diary that, while taking refuge in the winter in Nova Zemlya, he and his men became severely ill after eating polar bear liver. It is claimed that, in 1913, Antarctic explorers Douglas Mawson and Xavier Mertz were both poisoned (and Mertz died) from eating the livers of their sled dogs during the Far Eastern Party. Another study suggests, however, that exhaustion and diet change are more likely to have caused the tragedy.

aminoacyl-tRNA (aa-tRNA) Also aminoacylated tRNA and charged tRNA. A transfer RNA to which a cognate amino acid is chemically bonded; i.e. the product of a transesterification reaction catalyzed by an aminoacyl-tRNA synthetase. Aminoacyl-tRNAs bind to the aminoacyl site of the ribosome during translation.

Kingston Pike saw a boom in tourism in the 1930s and 1940s as it lay along a merged stretch of two cross-country tourism routes, the Dixie Highway and the Lee Highway. During the same period, traffic to the Smokies led to development along Chapman Highway (named for the park's chief promoter, David Chapman) in South Knoxville. In the late 1920s, General Lawrence Tyson donated land off Kingston Pike for McGhee Tyson Airport, named for his son, World War I aviator Charles McGhee Tyson (the airport has since moved to Blount County). In 1947, Knoxville replaced its streetcar system with buses. TVA's completion of Fort Loudoun Dam in 1943 brought modifications to Knoxville's riverfront. In 1946, travel writer John Gunther visited Knoxville, and dubbed the city, the "ugliest city" in America. He also mocked its puritanical laws regarding liquor sales and the showing of movies on Sunday, and noted the city's relatively high crime rate. While Knoxvillians vigorously defended their city, Gunther's comments nevertheless sparked discussions regarding the city's unsightliness and its blue laws. The ordinance forbidding the showing of movies on Sunday was done away with in 1946, with the help of the state legislature. Knoxville legalized packaged liquor in 1961, though the issue remained a contentious one for years.

The Association for Molecular Pathology (abbreviated AMP) is a professional association of individuals serving patients through molecular diagnostics testing. Founded in 1995, the Association has more than 3,100 members in over 50 countries. Molecular diagnostics is one of the fastest growing fields of health care. Molecular genetic testing provides patients and their doctors with accurate diagnosis of a broad range of cancers, infectious diseases, and inherited conditions. By identifying the exact molecular genetic alterations or biomarkers in a patient’s specimen, molecular genetic testing can identify treatment targets for personalized precision medicine that have improved outcomes for many patients. AMP is a volunteer-driven organization that concentrates on providing educational opportunities to practitioners and the broader medical community, advocating for the profession and the molecular professional, and advancing clinical care through the publication of evidence-based practice guidelines. AMP members work in academic and community medical centers, private and public health laboratories, government agencies, and the diagnostic manufacturing industry. Its membership includes pathologists, clinical laboratory scientists, technologists, trainees (who receive free membership while in training), clinicians and other health care personnel, government employees involved in regulatory oversight, and individuals in the in vitro diagnostics and pharmaceutical industries.

Sources: en.wikipedia.org

Background from the literature

Avicenna discouraged opium's use except as a last resort, preferring to address the causes of pain rather than trying to minimize it with analgesics. Many of Avicenna's observations have been supported by modern medical research. Exactly when the world became aware of opium in India and China is uncertain, but opium was mentioned in the Chinese medical work Kaibao Bencao (973 AD) By 1590 AD, opium poppies were a staple spring crop in the Subahs of Agra region. The physician Paracelsus (c. 1493–1541) is often credited with reintroducing opium into medical use in Western Europe, during the German Renaissance. He extolled opium's benefits for medical use. He also claimed to have an "arcanum", a pill which he called laudanum, that was superior to all others, particularly when death was to be cheated. ("Ich hab' ein Arcanum – heiss' ich Laudanum, ist über das Alles, wo es zum Tode reichen will.") Later writers have asserted that Paracelsus' recipe for laudanum contained opium, but its composition remains unknown.

CEEs are naturally occurring estrane steroids. They are in conjugate form, as the sodium salts of the C17β sulfate esters. The estrogens in CEEs, in their unconjugated active forms, include bioidentical human estrogens like estradiol and estrone as well as equine-specific estrogens such as equilin and 17β-dihydroequilin. The equine estrogens differ from human estrogens in that they have additional double bonds in the B ring of the steroid nucleus. CEEs contain both 17β-estrogens like estradiol and 17β-dihydroequilin and the C17α epimers like 17α-estradiol and 17α-dihydroequilin.

=== Partial drying === To achieve 0.6-0.84 water activity in food products, partial drying is employed for raw food that naturally have a high amount of humectants such as raisins, apricots, prunes and sultanas. Humectants are solutes (such as sugar or salt) that immobilize water in food. The drying process removes free water, and the humectants in the product bind the rest of the water, not allowing it to be utilized for chemical reactions or for microbial use.

In the US, studies have shown that fruit flies that infest orange groves were becoming resistant to malathion, a pesticide used to kill them. In Hawaii and Japan, the diamondback moth developed a resistance to Bacillus thuringiensis, which is used in several commercial crops including Bt corn, about three years after it began to be used heavily. In England, rats in certain areas have developed such a strong resistance to rat poison that they can consume up to five times as much of it as normal rats without dying. DDT is no longer effective in controlling mosquitoes that transmit malaria in some places, a fact that contributed to a resurgence of the disease. In the southern United States, the weed Amaranthus palmeri, which interferes with production of cotton, has developed widespread resistance to the herbicide glyphosate. In the Baltic Sea, decreases in salinity has encouraged the emergence of a new species of brown seaweed, Fucus radicans.

==== Force generation ==== Muscle force is proportional to physiological cross-sectional area (PCSA), and muscle velocity is proportional to muscle fiber length. The torque around a joint, however, is determined by a number of biomechanical parameters, including the distance between muscle insertions and pivot points, muscle size and architectural gear ratio. Muscles are normally arranged in opposition so that when one group of muscles contracts, another group relaxes or lengthens. Antagonism in the transmission of nerve impulses to the muscles means that it is impossible to fully stimulate the contraction of two antagonistic muscles at any one time. During ballistic motions such as throwing, the antagonist muscles act to 'brake' the agonist muscles throughout the contraction, particularly at the end of the motion. In the example of throwing, the chest and front of the shoulder (anterior deltoid) contract to pull the arm forward, while the muscles in the back and rear of the shoulder (posterior deltoid) also contract and undergo eccentric contraction to slow the motion down to avoid injury. Part of the training process is learning to relax the antagonist muscles to increase the force input of the chest and anterior shoulder. Contracting muscles produce vibration and sound. Slow twitch fibers produce 10 to 30 contractions per second (10 to 30 Hz). Fast twitch fibers produce 30 to 70 contractions per second (30 to 70 Hz). The vibration can be witnessed and felt by highly tensing one's muscles, as when making a firm fist.

Sources: en.wikipedia.org

Frequently asked questions

Why are clinical results inconsistent?

Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.

In which countries is thymosin alpha 1 approved?

Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.

How is the peptide characterized in review articles?

Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Network